´
V. C e sar, S. Bellemin-Laponnaz, L. H. Gade
FULL PAPER
bulb distillation to yield a colorless solution of the expected bromo-
oxazoline in THF (concentration of about 18% w/w) (2.58 g of pure
(175 mg, 84%). Crystallization from CH2Cl2/Et2O gave small or-
ange crystals suitable for an X-ray diffraction study. 1H NMR
1
3
compound, 53%). H NMR (CDCl3): δ ϭ 4.12 (s, 2 H, oxa CH2),
(CDCl3): δ ϭ 7.30 (d, J ϭ 2.1 Hz, 1 H, 4/5-im CH), 6.95 (s, 2 H,
1.34 (s, 6 H, CH3) ppm. 13C{1H} NMR (CDCl3): δ ϭ 141.4 (NCO), CHmes), 6.62 (d, J ϭ 2.1 Hz, 1 H, 4/5-im CH), 4.52 (s, 2 H, oxa
3
76.3 (CH), 71.6 (CH2), 25.5 (CH3) ppm.
CH2), 3.58 (br. m, 4 H, 2/3/5/6-nbd CH), 3.45 (m, 2 H, 1/4-nbd
CH), 2.30 (s, 3 H, para CH3), 2.20 (s, 6 H, ortho CH3), 1.45 (s, 6
1-(4,5-Dihydro-4,4-dimethyloxazol-2-yl)-3-mesitylimidazolium Bro-
mide (2): 1-Mesityl-1H-imidazole (1.11 g, 5.96 mmol) was added to
a solution of 1 (1.11 g, 6.23 mmol) in THF (ca. 1.0 ) and the
mixture was heated at 50 °C for 2 hours. A white solid precipitated
during this period of time. After cooling, diethyl ether (10 mL) was
added to complete the precipitation. The product was filtered,
washed with diethyl ether (2 ϫ 10 mL) and dried in vacuo to yield
1.80 g (82%) of 2 as a white powder. 1H NMR (CDCl3): δ ϭ 10.57
H, oxa CH3), 0.98 (s, 2 H, CH2nbd) ppm. 13C{1H} NMR (CDCl3):
13
δ ϭ 183.6 (d, 1J103
ϭ 55 Hz, N2C), 155.6 (NCO), 139.5
Rh,
C
(Cmes), 135.6 (Cmes), 133.6 (Cmes), 128.8 (CHmes), 123.5 (CHim),
115.6 (CHim), 84.6 (oxa CH2), 67.3 (oxa C4), 60.1 (nbd CH2 ), 49.2
(1/4-nbd CH), 28.5 (oxa CH3), 21.1 (para CH3), 18.6 (ortho CH3)
ppm. MS (ESI): m/z (%) ϭ 478.13 (100) [M Ϫ Br]ϩ. FT-IR (KBr):
ν˜ ϭ 1664 cmϪ1 (s, νCϭN). C24H29BrN3ORh (558.32): calcd. C
51.63, H 5.23, N 7.53; found C 51.11, H 5.19, N 7.34.
4
3
4
(t, J ϭ 1.5 Hz, 1 H, NCHN), 8.14 (dd, J ϭ 2.1, J ϭ 1.5 Hz, 1
H, 4,5-imidazolium CH), 7.60 (dd, 3J ϭ 2.1, 4J ϭ 1.5 Hz, 1 H, 4,5-
imidazolium CH), 7.00 (s, 2 H, mesityl CH), 4.53 (s, 2 H, CH2),
2.32 (s, 3 H, para CH3), 2.16 (s, 6 H, ortho CH3), 1.45 (s, 6 H,
oxazoline CH3) ppm. 13C{1H} NMR (CDCl3): δ ϭ 148.8 (CNO),
142.2 (mesityl C), 138.3 (N2C), 134.4, 130.5 (mesityl C), 130.4
(mesityl CH), 125.8, 121.3 (imidazolium CH), 83.2 (CH2), 68.7 (ox-
azoline C4), 28.4 (ortho CH3 ), 21.5 (para CH3), 18.4 (oxazoline
CH3) ppm. MS (FAB): m/z (%) ϭ 284.0 [M]ϩ (100), 187.0 [M Ϫ
(η4-1,5-Cyclooctadiene){1-(4,5-dihydro-4,4-dimethyloxazol-2-yl)-3-
mesitylimidazol-2-ylidene}rhodium(
I)
Hexafluorophosphate (5):
Solid KPF6 (34 mg, 0.185 mmol, 1.5 equiv.) was added to an or-
ange solution of 3 (70 mg, 0.122 mmol) in CH2Cl2 (5 mL). De-
gassed water (5 mL) was subsequently added and the mixture was
stirred vigorously for 30 minutes. The organic layer was decanted
and the aqueous layer was washed with an additional 5 mL of
CH2Cl2. The organic layers were combined, dried over Na2SO4 and
the volatiles were removed in vacuo. After washing with Et2O
(5 mL) and drying, an orange powder was isolated (76 mg, 98%).
Suitable crystals for an X-ray diffraction study were obtained by
slow diffusion of Et2O into a saturated solution of 5 in CH2Cl2/
Et2O. 1H NMR (CDCl3): δ ϭ 7.50 (d, 3J ϭ 2.1 Hz, 1 H, 4/5-im
C5H8NO]ϩ (22). FT-IR (KBr): ν˜
ϭ
1691 cmϪ1 (s, νCϭN).
C17H22BrN3O (364.29): calcd. C 56.05, H 6.09, N 11.54; found C
55.66, H 6.08, N 11.49.
Bromo(η4-1,5-cyclooctadiene){1-(4,5-dihydro-4,4-dimethyloxazol-2-
yl)-3-mesitylimidazol-2-ylidene}rhodium(I) (3): [RhCl(1,5-COD)]2
3
CH), 6.96 (s, 2 H, CHmes), 6.75 (d, J ϭ 2.1 Hz, 1 H, 4/5-im CH),
(48 mg, 0.098 mmol) and KOtBu (24 mg, 2.2 equiv.) were stirred in
THF (5 mL) for 30 min at room temperature. The resulting dark
yellow solution was then slowly added to a suspension of the imida-
zolium salt 2 (72 mg, 2.0 equiv.) in THF (10 mL) at Ϫ78 °C. The
mixture was allowed to warm to room temperature overnight. The
bright yellow solution was centrifuged, the supernatant was sepa-
rated and the solvents evaporated to give a yellow powder which
was washed with pentane (2Ϫ3 mL) and dried in vacuo to yield
compound 3 (97 mg, 86%). Suitable crystals for an X-ray diffrac-
tion studies were obtained by slow diffusion of Et2O into a solution
of 3 in CH2Cl2. 1H NMR (CDCl3, 298 K): δ ϭ 7.69 (d, 3J ϭ 2.1 Hz,
1 H, 4/5-im CH), 6.96 (s, 2 H, mes CH), 6.82 (d, 3J ϭ 2.1 Hz, 1 H,
5/4-im CH), 4.66 (s, 2 H, oxa CH3), 2.29 (s, 3 H, para CH3), 2.12
(br, 4 H, COD CH2), 2.08 (s, 6 H, ortho CH3), 1.74 (br, 4 H, COD
5.32Ϫ5.29 (m, 2 H, COD CH), 4.70 (s, 2 H, oxa CH2), 3.66Ϫ3.64
(m, 2 H, COD CH), 2.33 (s, 3 H, para CH3), 2.33Ϫ2.10 (m, 4 H,
COD CH2), 2.10 (s, 6 H, ortho CH3), 1.98Ϫ1.92 (m, 2 H, COD
CH2), 1.82Ϫ1.76 (m, 2 H, COD CH2), 1.49 (s, 6 H, oxa CH3) ppm.
1
13
13C{1H} NMR (CDCl3, 298 K): δ ϭ 174.2 (d, J103
C ϭ 54 Hz,
Rh,
N2C), 160.2 (NCO), 140.8, 134.2, 133.0 (Cmes), 129.7 (CHmes),
13
Rh,
125.3 (CHim), 118.2 (CHim), 97.6 (d, J103
ϭ 7.5 Hz, COD
C
13
CH), 85.1 (oxa CH2), 74.4 (d, J103
ϭ 13 Hz, COD CH), 67.9
Rh,
C
(oxa C4), 31.8, 29.1 (COD CH2), 27.4 (oxa CH3 ), 21.2 (para
CH3 ), 17.6 (ortho CH3 ) ppm. MS (ESI): m/z (%) ϭ 486.09 (100)
[RhL(CH3CN)2(H2O)]ϩ, 527.12 (46) [RhL(CH3CN)3(H2O)]ϩ. FT-
IR (KBr): ν˜ ϭ 1664 cmϪ1 (s, νCϭN). C25H33F6N3OPRh (639.42):
calcd. C 46.96, H 5.20, N 6.57; found C 46.9, H 5.35, N 6.65.
CH2), 1.49 (s, 6 H, oxa CH3) ppm. 13C{1H} NMR (CDCl3, 298 K):
{1-(4,5-Dihydro-4,4-dimethyloxazol-2-yl)-3-mesitylimidazol-2-
13
δ ϭ 177.2 (d, 1J103
ϭ 53 Hz, N2C), 158.8 (NCO), 140.4
Rh,
C
ylidene}(η4-2,5-norbornadiene)rhodium(
I)
Tetrafluoroborate (6):
(Cmes), 134.5 (Cmes), 133.6 (Cmes), 129.5 (CHmes), 125.2 (CHim),
118.8 (CHim), 84.3 (oxa CH2 ), 67.8 (oxa C4 ), 30.5 (br, COD CH2 ),
27.8 (oxa CH3), 21.2 (para CH3 ), 18.1 (ortho CH3) ppm. MS
(ESI): m/z (%) ϭ 486.09 (22) [M Ϫ Br Ϫ COD ϩ 2CH3CN ϩ
H2O]ϩ, 527.12 (100) [M Ϫ Br Ϫ COD ϩ 3CH3CN ϩ H2O]ϩ. FT-
IR (KBr): ν˜ ϭ 1677 cmϪ1 (s, νCϭN). C25H33BrN3ORh (574.36):
calcd. C 52.28, H 5.79, N 7.32; found C 51.82, H 5.66, N 7.38.
Solid NaBF4 (37 mg, 0.340 mmol, 2 equiv.) was added to an orange
solution of 4 (95 mg, 0.170 mmol) in CH2Cl2 (5 mL). Degassed
water (5 mL) was then added and the resulting red mixture was
stirred vigorously for 30 min. The organic layer was removed and
the aqueous layer was washed with an additional 5 mL of CH2Cl2.
The organic layers were combined, dried over Na2SO4 and the vol-
atiles were removed in vacuo. Crystallization of the crude material
from CH2Cl2/Et2O gave reaction product 6 in the form of long, red
needles (77 mg, 80%). Suitable crystals for an X-ray diffraction
study were obtained by slow diffusion of Et2O into a saturated
Bromo{1-(4,5-dihydro-4,4-dimethyloxazol-2-yl)-3-mesitylimidazol-2-
ylidene}(η4-2,5-norbornadiene)rhodium(
I) (4): Solid [RhCl(nbd)]2
(86 mg, 0.186 mmol) and KOtBu (46 mg, 0.41 mmol, 2.2 equiv.)
were weighed and placed in a Schlenk tube. THF (6 mL) was then solution of 4 in CH2Cl2/Et2O. 1H NMR (CDCl3): δ ϭ 7.52 (d, 3J ϭ
added and the reaction mixture was stirred for 30 minutes at ambi-
ent temperature. The solution thus obtained was slowly added to a
2.1 Hz, 1 H, 4/5-im CH), 6.81 (s, 2 H, CHmes), 6.67 (d, 3J ϭ 2.1 Hz,
1 H, 4/5-im CH), 5.13 (br, 2 H, nbd CH), 4.76 (s, 2 H, oxa CH2),
suspension of the imidazolium salt 2 (136 mg, 0.373 mmol, 2.0 3.87 (br, 2 H, nbd CH), 3.52 (br, 2 H, 1/4nbd CH), 2.26 (s, 3 H,
equiv.) in THF (12 mL) at Ϫ78 °C. The mixture was allowed to
warm to ambient temperature overnight and was centrifuged. The
resulting orange-red supernatant was separated and the solvents
evaporated in vacuo. The crude solid was washed two or three times
with pentane (5 mL). Complex 4 was obtained as an orange powder
para CH3), 2.07 (s, 6 H, ortho CH3), 1.33 (s, 6 H, oxa CH3), 1.31
(s, 2 H, nbd CH2) ppm. 13C{1H} NMR (CDCl3): δ ϭ 175.3 (d,
13
1J103
C ϭ 59 Hz, N2C), 161.8 (NCO), 140.5, 134.4, 132.5 (Cmes),
Rh,
129.2 (CHmes), 124.7 (CHim), 117.4 (CHim), 85.8 (oxa CH2), 82.2
(oxa C4), 66.3, 65.8 (nbd CH), 59.0 (nbd CH2), 53.9, 53.5 (1/4-nbd
3442
2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Eur. J. Inorg. Chem. 2004, 3436Ϫ3444